Summary

Eligibility
for people ages 18-65 (full criteria)
Location
at UC Davis
Dates
study started
study ends around
Principal Investigator
by Rachael Callcut, MD (ucdavis)
Headshot of Rachael Callcut
Rachael Callcut

Description

Summary

The long-term goal of the clinical trial is to develop effective, safe, and easily administered life-saving treatments for patients with moderate to severe traumatic brain injury (TBI).

Patients with moderate to severe TBI will randomly receive either:

  1. Standard of care treatment and normal saline
  2. Standard of care treatment and one dose of valproic acid (VPA) at a lower dose or a higher dose

Official Title

Multi-institutional Phase 2/3 Trial of Valproic Acid in Patients With Moderate to Severe Traumatic Brain Injury

Details

The specific aim is to determine whether giving VPA at either a 50 mg/kg dose or a 100 mg/kg is safe (as measured by adverse events after treatment) in patients with moderate to severe TBI due to brain bruises.

Keywords

Moderate Traumatic Brain Injury (TBI), Severe Traumatic Brain Injury, TBI, traumatic brain injury, VPA, valproic acid, Traumatic Brain Injuries, Valproic Acid, Saline Solution, Valproic Acid (VPA)

Eligibility

You can join if…

Open to people ages 18-65

  1. Male or female between the ages of 18 and 65 years.
  2. Body Mass Index between 18 kg/m2 and 35 kg/m2.
  3. Females must be surgically sterilized, postmenopausal, or have a negative urine pregnancy test.
  4. Moderate to severe TBI: Glasgow Coma Scale (GCS) 3-12.
  5. Cerebral trauma confirmed on the initial CT scan with radiographic findings consistent with Brain Injury Guidelines category 3 (BIG3) criteria

You CAN'T join if...

  1. Persons with known history of adverse reactions to VPA
  2. Persons with known history of hepatitis B or C or clinical history of hepatic dysfunction, pancreatitis, or renal insufficiency.
  3. Persons with a known history of thrombocytopenia.
  4. Persons with platelet count less than 100,000 per microliter of blood.
  5. Persons with 2nd or 3rd degree burns of any size and location.
  6. Female subjects who are pregnant or lactating.
  7. Persons who are currently incarcerated or are in police custody.
  8. Persons with inadequate venous access.
  9. Treatment cannot start within 120 minutes from the onset of injury
  10. Non-survivable injuries in the estimation of the attending trauma surgeon.
  11. Interfacility transfers
  12. The time of injury is unknown
  13. Patients in hemorrhagic shock with a systolic blood pressure of <90 mmHg on initial evaluation.
  14. Persons with a known "do not resuscitate" order prior to randomization
  15. Persons with a research "opt out" bracelet
  16. Persons who are currently enrolled in another clinical trial.
  17. Greater than 90 minutes between the onset of injury and arrival to the hospital

Locations

  • University of California, Davis
    Sacramento 5389489 California 5332921 95817 United States
  • University of Southern California
    Los Angeles 5368361 California 5332921 90089-0701 United States

Lead Scientist at University of California Health

  • Rachael Callcut, MD (ucdavis)
    Associate Dean, Data Science & Innovation, School of Medicine. Authored (or co-authored) 103 research publications

Details

Status
not yet accepting patients
Start Date
Completion Date
(estimated)
Sponsor
Northwestern University
ID
NCT07166393
Phase
Phase 2/3 research study
Study Type
Interventional
Participants
Expecting 432 study participants
Last Updated